B

Bristol Myers Squibb

Makes drugs for cancer, blood and immune diseases

Facilities Maintenance Supervisor

Full-TimeUpdated on 10/24/2026Deadline 12/31/26
$107.9k - $130.8k+ Discretionary incentive cash + Stock opportunities
Senior
Associate's
Indianapolis, IN, USA
In PersonIndianapolis-based; occasional after-hours/on-call coverage may be needed.
General Maintenance & RepairBuilding & Property Maintenance
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • A high school diploma or equivalent is required.
  • A technical certification, trade school education, or an Associate's degree in a relevant field such as electrical, mechanical, HVAC, or similar is preferred.
  • At least 5 years of hands-on facilities maintenance experience, including at least 1–2 years in a lead or supervisory capacity, is required; experience in pharmaceutical, healthcare, biotech, or another regulated industry is preferred.
  • Experience reviewing and overseeing contractor-performed test and air balance activities and HEPA certifications in cleanroom, controlled environment, pharmaceutical, healthcare, biotech, or other regulated facilities is preferred.
  • Experience coordinating outside contractors or vendors for maintenance, calibration, or facility improvement work is required.
  • Familiarity with Good Manufacturing Practice, Environmental Health and Safety, and Nuclear Regulatory Commission compliance standards is required; radiopharmaceutical or sterile/injectable environment experience is a plus.
  • Strong working knowledge of building systems, including HVAC, electrical, plumbing, chilled water, compressed air, and emergency power, is required.
  • Demonstrated ability to lead, train, and hold a small technical team accountable in a fast-paced, regulated environment is required.
  • Effective vendor and contractor management skills, including scheduling, scope clarification, and quality verification, are required.
  • Ability to evaluate test and air balance reports and HEPA certification documentation, identify unacceptable results or documentation gaps, and coordinate resolution with contractors, Quality, and Engineering stakeholders is required.
  • Proficiency with computerized maintenance management system platforms such as BMRAM, Maximo, or SAP, and ability to maintain accurate maintenance and calibration records, are required.
  • Working knowledge of building automation systems and standard diagnostic tools, including volt/ohm meters, current clamps, and signal generators, is required.
  • Strong organizational and prioritization skills to balance hands-on troubleshooting with supervisory and administrative duties are required.
  • Clear written and verbal communication skills, including reporting status and issues to site leadership, are required.
  • A high degree of personal accountability, a safety mindset, and professional integrity are required.
  • Ability to use AI tools to enhance individual productivity and quality of work is required.
  • Ability to stand, walk, climb ladders and stairs, bend, stoop, push, pull, and reach regularly, and lift or move up to 50 pounds, is required.
  • Close and distance vision are required.
  • Ability to work periodically in a Good Manufacturing Practice cleanroom environment, including gowning, and occasional exposure to mechanical and utility spaces, is required.
Responsibilities
  • Directly supervise, schedule, and coach a team of 3–5 Facilities Technicians by assigning daily work, reviewing performance, and supporting hiring, onboarding, and development.
  • Plan and prioritize preventive and corrective maintenance work orders across HVAC, electrical, plumbing, chilled water, compressed air, backup generator, UPS, and lighting systems to minimize downtime and ensure continuity of operations.
  • Serve as the primary day-to-day site contact for contractors and vendors performing maintenance, calibration, and minor improvement work; coordinate scheduling, site access, and scope confirmation, and verify work quality and completion.
  • Review and supervise contractors performing test and air balance activities and HEPA certification work, ensuring reports, results, and field execution meet site expectations, Good Manufacturing Practice requirements, and applicable cleanroom performance standards.
  • Support quality event management for facilities-related issues by providing technical input, leading or supporting change controls, and contributing to corrective and preventive action and deviation investigations and responses.
  • Own and maintain the site computerized maintenance management system work order queue for the maintenance team, ensuring accurate, timely closure of work orders and up-to-date equipment and calibration records.
  • Conduct and oversee routine facility walkthroughs and inspections, identify safety, performance, or compliance issues, and drive timely resolution.
  • Monitor critical utility systems and respond to or direct the team's response to equipment alarms and facility issues, including after-hours and on-call escalations as needed.
  • Ensure maintenance activities comply with Good Manufacturing Practice, Nuclear Regulatory Commission, and Environmental Health and Safety requirements, and support internal and external inspections as a subject matter resource for maintenance operations.
  • Support commissioning and turnover activities for new equipment and facility spaces, coordinating technician and contractor involvement as needed.
  • Track and report team key performance indicators, including work order aging, preventive maintenance completion rate, and contractor performance, to the Associate Director of Facilities Engineering.
  • Assist with authoring and revising standard operating procedures, work instructions, and computerized maintenance management system procedures related to maintenance activities.
  • Manage minor maintenance and improvement project budgets and quotes, escalating capital-scale needs to the Associate Director.
  • Participate in safety initiatives, emergency response planning, and drills, and promote a strong safety culture within the maintenance team.
Desired Qualifications
  • Experience reviewing and overseeing contractor-performed test and air balance activities and HEPA certifications in cleanroom, controlled environment, pharmaceutical, healthcare, biotech, or other regulated facilities.
  • Radiopharmaceutical or sterile/injectable environment experience.

About the company

Bristol Myers Squibb discovers, develops and sells prescription medicines for serious illnesses, including cancer, blood disorders, immune diseases and heart disease, for patients treated by doctors and hospitals around the world. Its best-known drug is Opdivo, an immunotherapy that helps the body's own immune system find and attack many kinds of cancer. Researchers develop drug candidates in its labs or bring them in through acquisitions and partnerships, then test them in clinical trials to win regulatory approval. The company makes and markets the approved medicines and earns its revenue from sales of patent-protected drugs. Its roots go back to a business founded in 1887, and it is based in Lawrence Township, New Jersey.

Company Size

10,001+

Company Stage

IPO

Headquarters

Lawrence Township, New Jersey

Founded

1887

Get referred to Bristol Myers Squibb

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sales are beating forecasts: BMS raised 2026 revenue guidance to $49 billion to $50 billion in July 2026.
  • Newer drugs carry the business: they made $7.6 billion of $13.0 billion in sales in the June 2026 quarter.
  • Manufacturing careers are expanding: a $2.3 billion Houston campus announced in August 2026 will add nearly 500 skilled roles.

What critics are saying

  • Job security is shaky: BMS added 265 New Jersey layoffs in September 2026, bringing its 2026 state cuts to 718.
  • A patent cliff looms: Eliquis and Opdivo, its two biggest drugs, lose US exclusivity around 2028.
  • Older drugs are shrinking fast: Revlimid sales fell 49% to $425 million in the June 2026 quarter as generics spread.

What makes Bristol Myers Squibb unique

  • BMS owns a psychiatry first: Cobenfy treats schizophrenia without blocking dopamine, unlike antipsychotics used for decades.
  • Its top seller is shared: BMS splits Eliquis blood thinner profits roughly equally with Pfizer in most markets.
  • BMS reengineers patients' own immune cells: it sells two CAR T therapies, Breyanzi and Abecma, for blood cancers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours
  • Hybrid Work Options
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

8%

1 year growth

7%

2 year growth

7%
Yahoo Finance
Oct 23rd, 2026
Three defensive stocks to buy as AI selloff hits: BMY, Colgate and Gilead offer dividends

As investors question the costs and returns of the AI boom, some are turning to defensive stocks in healthcare and consumer goods. Three that pay quarterly dividends stand out: Bristol Myers Squibb, Colgate-Palmolive, and Gilead Sciences. Bristol Myers Squibb shares are up 14.3% this year, with a forward dividend yield of 4.3% and 18 straight years of increases. Second-quarter revenue reached $13 billion, with newer products making up nearly 60%. Colgate-Palmolive is up 20.2% this year and has raised its dividend for 64 years in a row. It reported second-quarter revenue of $5.36 billion. Gilead shares have gained 26%, against 13% for the S&P 500. Second-quarter HIV sales rose 12% to $5.7 billion.

Market Chameleon
Oct 19th, 2026
Bristol Myers to bring 12 oral presentations and nearly 60 oncology disclosures to ESMO 2026.

Bristol Myers to bring 12 oral presentations and nearly 60 oncology disclosures to ESMO 2026. 19 October 2026, 8:50 AM By Market Chameleon Produced with AI assistance and reviewed by Market Chameleon staff. Bristol Myers Squibb (BMY) said it will present new data across its oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) 2026 Congress (October 23-27 in Madrid), spanning 12 oral presentations and nearly 60 disclosures. The company's update spotlights multiple modalities across solid tumors, including late-breaking Phase 3 studies for izalontamab brengitecan (iza-bren) and late-breaking global Phase 2 data for pumitamig, alongside long-term survival results for Opdivo plus Yervoy. ESMO 2026 presence emphasizes late-breaking Phase 3 and Phase 2 catalysts across solid tumors. In the announcement, Bristol Myers highlighted two late-breaking, Phase 3 studies of izalontamab brengitecan (iza-bren), described as a potential first-in-class EGFR x HER3 bispecific antibody-drug conjugate (ADC), in EGFR-mutated non-small cell lung cancer (PANKU-Lung01) and HR+/HER2- breast cancer (PANKU-Breast01).

Savills
Oct 14th, 2026
San diego Q3 2026 life sciences market report.

San diego Q3 2026 life sciences market report. 14 October 2026 Market highlights. * Overall vacancy increased 60 basis points year over year to 28.5% in Q3 2026, up from 27.9% in Q3 2025. The increase was driven by direct vacancy, which rose to 25.8%, while sublease vacancy declined to 2.8%. * Venture capital funding slowed considerably in 2026, with $1.4 billion raised across 113 deals through Q3, down 34.1% year over year and marking the lowest Q1 through Q3 total since 2022. * Alexandria Real Estate delivered a 427,000-square-foot R&D hub for Bristol Myers Squibb at Campus Point, establishing the company as an anchor tenant at the 2.9- million-square-foot life sciences campus.

Yahoo Finance
Oct 13th, 2026
Eli Lilly beats Bristol Myers Squibb on growth: $65.2B revenue, 45% rise vs. $48.2B

A comparison of Bristol Myers Squibb and Eli Lilly concludes that Lilly is the better healthcare stock to buy in 2026, even at a premium. Lilly's 2025 revenue rose about 45% to $65.2 billion, with net income near $21 billion. Bristol Myers' revenue slipped 0.2% to $48.2 billion, though it returned to a net income of $7.1 billion after an $8.9 billion loss in 2024. Lilly trades at 33.8 times forward earnings against 8.2 times for Bristol Myers. The article says Bristol Myers is cheap for good reason, citing pricing pressure, patent expiries, and an unpredictable recovery. Lilly's weight-loss drugs Zepbound and Mounjaro are expected to lift 2026 revenue above 30%, to $88.6 billion. Bristol Myers is forecast to grow 3% to $49.9 billion.

Chinese LGZ
Oct 9th, 2026
Bristol Myers Squibb unveils $2.3 billion investment in cutting-edge Houston pharma facility.

Bristol Myers Squibb unveils $2.3 billion investment in cutting-edge Houston pharma facility. Source link: https://houston365.info/2026/10/09/bristol-myers-squibb-unveils-2-3-billion-investment-in-cutting-edge-houston-pharma-facility/ Bristol Myers Squibb strengthens Houston's life sciences sector with $2.3 billion facility. Bristol Myers Squibb is set to transform Houston's pharmaceutical landscape through a landmark $2.3 billion investment in a cutting-edge manufacturing plant. This initiative, developed in collaboration with the Greater Houston Partnership, aims to elevate the company's production capabilities while cementing Houston's status as a burgeoning center for biopharmaceutical innovation. The project is projected to generate hundreds of skilled jobs and stimulate substantial economic growth within the region. Project overview and strategic importance. The new facility will incorporate the latest manufacturing technologies to optimize efficiency and product quality. With over 1,200 new roles anticipated in scientific research, engineering, and production, the plant will serve as a catalyst for workforce development and community engagement. This expansion aligns with Bristol Myers Squibb's vision to accelerate the delivery of novel therapies and reinforces Houston's growing influence in the life sciences ecosystem. * Innovative manufacturing processes: Adoption of advanced automation and quality control systems. * Employment opportunities: Creation of more than 1,200 specialized jobs across multiple disciplines. * Community collaboration: Strengthening partnerships with local universities and healthcare institutions to foster innovation. | Investment Detail | Information | | Total... | - - Author: Samuel Brown Publish date: 2026-10-09 15:23:00 Copyright for syndicated content belongs to the linked Source. - - 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8